Clinical outcomes with drug-eluting stents, bare-metal stents, and bioresorbable scaffolds implanted in patients with AMI treated with primary PCI. Data from the Prague-18 trial

Abstract Background Drug-eluting stents (DESs) are the recommended choice of for primary PCI. Purpose/Methods The study aimed to determine why interventional cardiologists used non-DESs and how they had influenced patient prognosis. efficacy safety outcomes different were also compared in treated with either prasugrel or ticagrelor. Results Of PRAGUE 18 patients, 749 (67.4%) DESs, 296 (26.6%) BMS, 66 (5.9%) BVS. Cardiogenic shock at presentation left main disease, especially as culprit lesion, right coronary artery stenosis reasons BMS selection. incidence net-clinical EP (CV death, nonfatal MI, stroke, major bleeding, revascularization) 7 days was 2.6% vs. 6.5%, 3.0% BMSs, BVSs, respectively (HR 2.7; 95% CI 1.419–5.15, P=0.002 DES 1.25 (0.29–5.39) BVS DES, P=0.76). Patients BMSs higher risk death 30 2.20; 1.01–4.76; P=0.045), one year 2.1; 1.19–3.69; P=0.01); composite cardiac re-MI stroke 1.66; 1.0–2.74; P=0.047) year. associated significantly rate EPs Conclusion highest profile preferably contrary a cardiovascular events FUNDunding Acknowledgement Type funding sources: Public Institution(s). Main source(s): Charles University Cardiovascular Research Program P-35 Q-38, University, Czech Republic